Document is current

Article History

Received: 8 June 2025

Accepted: 24 October 2025

First Online: 6 November 2025

Declarations

:

: The study was conducted in accordance with the Declaration of Helsinki. National legislation governing the use of registry data was adhered to, and when required, written informed consent was obtained from patients, or the patients were informed about inclusion in a registry and the right to opt out. The study was approved by the Ethical Review Board of Stockholm, Sweden (Dnr 2018/1591–31/2), the Ethical Committee of the University of Miyazaki (o-0495) and the Japanese Society of Nephrology (no. 68).

: Not applicable.

: M.W. reports honoraria from Astra Zeneca, Bayer and CSL Vifor and participation in advisory board for CSL Vifor. S.K. reports consulting fees from Asahi Kasei Pharma and honoraria from Kissei Pharmaceutical, Chugai Pharmaceutical, Tejin Health Care, participation in advisory board for Kissei Pharmaceutical. K.T. reports honoraria from Sanofi-Genzyme, Takeda, Boehringer-Ingelheim and membership in ERA Scientific Advisory Board. R.S. reports travel grants from Alpine Immune Sciences. M.C. reports honoraria from Bayer, Astra Zeneca, Berlin Chemie Menarini and BRK-B stocks and Valamar d.d. stocks. C.G. reports travel grants from Hansa Pharmaceuticals, membership of data safety monitoring board for TURING trial and being chair of UK Living Donor Network. Y.S. reports consulting fees from Otsuka Pharmaceutical, Novartis, Chinook Therapeutics, ARGENX, BioCryst, Alexion Pharmaceuticals, Renalys, Alpine and George Clinical and honoraria from Kyowa Kirin, Novartis, Mitsubishi Tanabe, Otsuka Pharmaceutical, Daiichi Sankyo, AstraZeneca, Boehringer Ingelheimand Chinook Therapeutics. M.S. reports consulting fees from CSL Vifor and Hansa Biopharma (to employer), honoraria from Otsuka Pharmaceutical and participation on advisory board for Novartis.